SEC Company Response from MERIDIAN BIOSCIENCE INC (CIK 0000794172) — Dec 18, 2020
MERIDIAN BIOSCIENCE INC (CIK 0000794172)
Date: Dec. 18, 2020 · CIK: 0000794172 · Accession: 0000892251-20-000035
AI Filing Summary & Sentiment
File numbers found in text: 333-250878
Show Raw Text
CORRESP
1
filename1.htm
Meridian Bioscience, Inc.
3471 River Hills Drive
Cincinnati, Ohio 45244
December 18, 2020
Via Edgar
1933 Act Filing Desk
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re:
File No. 333-250878
Registration Statement on Form S-3
Filed November 23, 2020
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, the registrant named below hereby requests that the effective date
of the Registration Statement on Form S-3, File No. 333-250878, be accelerated to, and that the Registration Statement be declared effective at, 10:00 a.m. (Washington D.C. time) on December 23, 2020 or as soon as practical thereafter. In this
connection, the registrant confirms that it is aware of its obligations under the Securities Act of 1933 and the Securities Exchange Act of 1934 as such obligations relate to the proposed offering of securities.
In addition, the registrant acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it
does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement
effective, does not relieve the registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Meridian Bioscience, Inc.
By:/s/ Bryan T. Baldasare
Bryan T. Baldasare,
Executive Vice President
and Chief Financial Officer
cc: Mr. Mark Reuter (Keating Muething & Klekamp PLL)